Drugs / Conjugated Linoleic Acid
Conjugated Linoleic Acid
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial · 1 met primary | ||||||
| Phase 0 | NCT00908791 | Jun 2009 → Mar 2013 | breast cancer | Dartmouth-Hitchcock Medical Center | Completed | Met primary |
| Phase 11 trial | ||||||
| Phase 1 | NCT00951158 | Mar 2010 → Dec 2012 | cancer | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00347373 | Aug 2004 → Sep 2005 | obesity disorder | University of North Carolina | Completed | No outcome recorded |
| — | NCT00473902 | Aug 2003 → Sep 2004 | muscular atrophy | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00204932 Comparator | Jul 2004 → Mar 2005 | obesity disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conjugated linoleic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00204932 ↗ |
| Known as | CLA | “We examined whether creatine monohydrate (CrM) and conjugated linoleic acid (CLA) could enhance strength gains and improve body composition (i.e., increase fat-free mass (FFM);...” NCT00473902 ↗2“Conjugated linoleic acid (CLA), a naturally occurring dietary fatty acid, has been found to reduce weight gain and dramatically decrease fat mass in animals.” PMID 16924272 ↗ Aug 2006 “Conjugated Linoleic Acid (CLA)” NCT00908791 ↗ |
| Known as | Tonalin | “Tonalin Conjugated linoleic acid (dietary supplement)” NCT00347373 ↗ |
| Action | Inhibit | “reduced Spot 14 (THRSP, S14) and Fatty Acid Synthase (FASN) gene expression” NCT00908791 ↗ |
| Route | Oral | “oral soft gel capsules will be administered” NCT00908791 ↗ |
| Target | FASN | “reduced Spot 14 (THRSP, S14) and Fatty Acid Synthase (FASN) gene expression” NCT00908791 ↗ |
| Target | THRSP | “reduced Spot 14 (THRSP, S14) and Fatty Acid Synthase (FASN) gene expression” NCT00908791 ↗ |